These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31387791)

  • 21. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 1998 Nov; 41(24):4903-9. PubMed ID: 9822559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands.
    Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH
    Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
    Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
    J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Substituted
    Lee B; Taylor M; Griffin SA; McInnis T; Sumien N; Mach RH; Luedtke RR
    Molecules; 2021 May; 26(11):. PubMed ID: 34073405
    [No Abstract]   [Full Text] [Related]  

  • 26. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
    Vangveravong S; Zhang Z; Taylor M; Bearden M; Xu J; Cui J; Wang W; Luedtke RR; Mach RH
    Bioorg Med Chem; 2011 Jun; 19(11):3502-11. PubMed ID: 21536445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Syntheses and pharmacological evaluation of two potent antagonists for dopamine D4 receptors: [11C]YM-50001 and N-[2-[4-(4-Chlorophenyl)-piperizin-1-yl]ethyl]-3-[11C]methoxybenzamide.
    Zhang MR; Haradahira T; Maeda J; Okauchi T; Kawabe K; Noguchi J; Kida T; Suzuki K; Suhara T
    Nucl Med Biol; 2002 Feb; 29(2):233-41. PubMed ID: 11823129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands.
    Zhou B; Hong KH; Ji M; Cai J
    Chem Biol Drug Des; 2018 Sep; 92(3):1597-1609. PubMed ID: 29710404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A structure-affinity relationship study on derivatives of N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a high-affinity and selective D(4) receptor ligand.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 2000 Jan; 43(2):270-7. PubMed ID: 10649982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, lipophilic properties, and binding affinities of potential ligands in positron emission tomography (PET) for visualization of brain dopamine D4 receptors.
    Lacivita E; De Giorgio P; Colabufo NA; Berardi F; Perrone R; Niso M; Leopoldo M
    Chem Biodivers; 2014 Feb; 11(2):299-310. PubMed ID: 24591318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}carboxamides.
    Heidler P; Zohrabi-Kalantari V; Calmels T; Capet M; Berrebi-Bertrand I; Schwartz JC; Stark H; Link A
    Bioorg Med Chem; 2005 Mar; 13(6):2009-14. PubMed ID: 15727854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors.
    Lacivita E; De Giorgio P; Lee IT; Rodeheaver SI; Weiss BA; Fracasso C; Caccia S; Berardi F; Perrone R; Zhang MR; Maeda J; Higuchi M; Suhara T; Schetz JA; Leopoldo M
    J Med Chem; 2010 Oct; 53(20):7344-55. PubMed ID: 20873719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.
    Newman AH; Grundt P; Cyriac G; Deschamps JR; Taylor M; Kumar R; Ho D; Luedtke RR
    J Med Chem; 2009 Apr; 52(8):2559-70. PubMed ID: 19331412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bivalent molecular probes for dopamine D2-like receptors.
    Huber D; Löber S; Hübner H; Gmeiner P
    Bioorg Med Chem; 2012 Jan; 20(1):455-66. PubMed ID: 22100258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.
    Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ
    Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Acute and Chronic Treatments with Dopamine D
    Thomsen M; Barrett AC; Butler P; Negus SS; Caine SB
    J Pharmacol Exp Ther; 2017 Jul; 362(1):161-176. PubMed ID: 28473458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, Biological, and Computational Evaluation of Substituted 1-(2-Methoxyphenyl)-4-(1-phenethylpiperidin-4-yl)piperazines and 1-(2-Methoxyphenyl)-4-[(1-phenethylpiperidin-4-yl)methyl]piperazines as Dopaminergic Ligands.
    Penjišević JZ; Šukalović VV; Andrić DB; Roglić GM; Šoškić V; Kostić-Rajačić SV
    Arch Pharm (Weinheim); 2016 Aug; 349(8):614-26. PubMed ID: 27335270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.
    Rangel-Barajas C; Malik M; Mach RH; Luedtke RR
    Neuropharmacology; 2015 Jun; 93():179-90. PubMed ID: 25698528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.